Literature DB >> 22968632

Glutathione-responsive nano-transporter-mediated siRNA delivery: silencing the mRNA expression of Ras.

C George Priya Doss1, S Debottam, C Debajyoti.   

Abstract

Gene therapy through antisense technology via intracellular delivery of a gene-silencing element is a promising approach to treat critical diseases like cancers. Ras acts as molecular switch, considered as one of the proto-oncogenes whose modification or mutation may promote tumor formation. The recent trends of nano-carrier-based drug delivery have gained superiority and proved to be 100 times more potent in drug delivery compared to standard therapies. The nano-based drug delivery has provided the basis of achieving successful target-specific drug delivery. Glutathione (GSH) is considered as one of the best and ubiquitous internal stimulus for swift destabilization of nano-transporters inside cells to accomplish proficient intracellular drug release. This concept has given a new hope to oncologists of modifying the existing drugs to be delivered to their desired destination. RNA interference is a primary tool in functional genomics to selectively silence messenger RNA (mRNA) expression, which can be exploited quickly to develop novel drugs against lethal disease target. Silencing of mRNA molecules using siRNA has also come of age to become one of the latest weapons developed in the concept of gene therapy. However, this strategy has severely failed to achieve target specificity especially to a tumor cell. In this context, we have proposed the incorporation of an antisense siRNA packed inside a GSH-responsive nano-transporter to be delivered specifically to a tumor cell against the sense mRNA of the Ras protein. It will limit the Ras-mediated activation of other proteins and transcription factors. Thus, it will knock down several differential gene expressions being regulated by Ras-activated pathways like enzyme-linked receptor kinase pathway. Henceforth, gene silencing technology through nano-drug delivery can be combined as a single weapon to terminate malignancy.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22968632     DOI: 10.1007/s00709-012-0451-1

Source DB:  PubMed          Journal:  Protoplasma        ISSN: 0033-183X            Impact factor:   3.356


  38 in total

1.  Double-stranded siRNA targeted to the huntingtin gene does not induce DNA methylation.

Authors:  Chang Won Park; Zongyu Chen; Betsy T Kren; Clifford J Steer
Journal:  Biochem Biophys Res Commun       Date:  2004-10-08       Impact factor: 3.575

2.  Enzymatic reduction of disulfide bonds in lysosomes: characterization of a gamma-interferon-inducible lysosomal thiol reductase (GILT).

Authors:  B Arunachalam; U T Phan; H J Geuze; P Cresswell
Journal:  Proc Natl Acad Sci U S A       Date:  2000-01-18       Impact factor: 11.205

Review 3.  RNA nanotechnology: engineering, assembly and applications in detection, gene delivery and therapy.

Authors:  Peixuan Guo
Journal:  J Nanosci Nanotechnol       Date:  2005-12

4.  Reduction of disulfide bonds within lysosomes is a key step in antigen processing.

Authors:  D S Collins; E R Unanue; C V Harding
Journal:  J Immunol       Date:  1991-12-15       Impact factor: 5.422

Review 5.  Delivery vehicles for small interfering RNA in vivo.

Authors:  Antonin R de Fougerolles
Journal:  Hum Gene Ther       Date:  2008-02       Impact factor: 5.695

6.  Reversibly stabilized multifunctional dextran nanoparticles efficiently deliver doxorubicin into the nuclei of cancer cells.

Authors:  Yu-Ling Li; Li Zhu; Zhaozhong Liu; Ru Cheng; Fenghua Meng; Jing-Hao Cui; Shun-Jun Ji; Zhiyuan Zhong
Journal:  Angew Chem Int Ed Engl       Date:  2009       Impact factor: 15.336

7.  Small interfering RNAs directed against beta-catenin inhibit the in vitro and in vivo growth of colon cancer cells.

Authors:  Udit N Verma; Rama M Surabhi; Aurelia Schmaltieg; Carlos Becerra; Richard B Gaynor
Journal:  Clin Cancer Res       Date:  2003-04       Impact factor: 12.531

Review 8.  Ocular delivery of nucleic acids: antisense oligonucleotides, aptamers and siRNA.

Authors:  Elias Fattal; Amélie Bochot
Journal:  Adv Drug Deliv Rev       Date:  2006-09-15       Impact factor: 15.470

9.  A combinatorial library of lipid-like materials for delivery of RNAi therapeutics.

Authors:  Akin Akinc; Andreas Zumbuehl; Michael Goldberg; Elizaveta S Leshchiner; Valentina Busini; Naushad Hossain; Sergio A Bacallado; David N Nguyen; Jason Fuller; Rene Alvarez; Anna Borodovsky; Todd Borland; Rainer Constien; Antonin de Fougerolles; J Robert Dorkin; K Narayanannair Jayaprakash; Muthusamy Jayaraman; Matthias John; Victor Koteliansky; Muthiah Manoharan; Lubomir Nechev; June Qin; Timothy Racie; Denitza Raitcheva; Kallanthottathil G Rajeev; Dinah W Y Sah; Jürgen Soutschek; Ivanka Toudjarska; Hans-Peter Vornlocher; Tracy S Zimmermann; Robert Langer; Daniel G Anderson
Journal:  Nat Biotechnol       Date:  2008-04-27       Impact factor: 54.908

Review 10.  Interfering with disease: a progress report on siRNA-based therapeutics.

Authors:  Antonin de Fougerolles; Hans-Peter Vornlocher; John Maraganore; Judy Lieberman
Journal:  Nat Rev Drug Discov       Date:  2007-06       Impact factor: 84.694

View more
  3 in total

1.  Design of PEI-conjugated bio-reducible polymer for efficient gene delivery.

Authors:  Joung-Pyo Nam; Soyoung Kim; Sung Wan Kim
Journal:  Int J Pharm       Date:  2018-04-23       Impact factor: 5.875

Review 2.  Recent advances in the development of gene delivery systems.

Authors:  Y K Sung; S W Kim
Journal:  Biomater Res       Date:  2019-03-12

Review 3.  Small GTPases: Structure, biological function and its interaction with nanoparticles.

Authors:  Siyang Song; Wenshu Cong; Shurong Zhou; Yujie Shi; Wenbing Dai; Hua Zhang; Xueqing Wang; Bing He; Qiang Zhang
Journal:  Asian J Pharm Sci       Date:  2018-07-31       Impact factor: 6.598

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.